Manipal Health Enterprises
FinMinutes Deep Business Model & Edge
Manipal Health Enterprises Limited operates a pan-India network of multispecialty hospitals providing comprehensive inpatient, outpatient, and diagnostic healthcare services. The company earns revenue primarily through hospital services, including complex tertiary and quaternary care procedures, diagnostic services, and the sale of pharmacy products.
What this company actually does — full breakdown ▾
Manipal Health Enterprises Limited is the largest multispecialty hospital network in India by bed capacity, operating 49 hospitals with 13,037 licensed beds across 14 states, including strong regional leadership in Karnataka, Maharashtra, Goa, and eastern India. The company delivers comprehensive clinical care spanning outpatient treatment, diagnostics, and advanced inpatient care. Its clinical focus is anchored in tertiary and quaternary care, specifically across its 'CONGO-R' specialties (cardiac sciences, oncology, neurosciences, gastro sciences, orthopedics, and renal sciences), which contribute over 64% of its gross inpatient revenue. Manipal serves a highly diversified patient base, supported by an omnichannel lead-management stack and an extensive network of 11,064 doctors. The company's geographic footprint balances presence across metro and non-metro cities, allowing it to capture urban demand while receiving complex referrals from adjacent rural districts. What sets Manipal apart is its repeatable playbook for integrating large transformative acquisitions—such as AMRI Hospitals, Medica Synergie, and Sahyadri Hospitals—enabling rapid scale, robust operational leverage, and industry-leading profitability margins in the Indian private healthcare delivery market.
- Hospital services — Revenue from inpatient and outpatient clinical treatments, procedures, and consultations.
- Pharmacy sales — Revenue from the sale of medical consumables and pharmacy items to patients.
- Diagnostic services — Revenue generated from clinical laboratory and diagnostic imaging services.
India's largest multispecialty hospital network by bed capacity (13,037 beds) with a highly successful, repeatable playbook for integrating major acquisitions, yielding industry-leading revenue growth (29.41% CAGR) and superior ROCE.
The Offer
Follow the Money — Use of Proceeds
- Repayment/ prepayment, in full or in part, of certain outstanding borrowings and accrued interest thereon availed by one of our Material Subsidiaries, namely, Manipal Hospitals Private Limited
- Acquisition of minority stake in our stepdown Subsidiary, Sahyadri Hospitals Private Limited
- General corporate purposes
FinMinutes IPO Score — How It's Built
Transparent, deterministic, computed from the filing — not an opinion. Open any component below to see exactly what it measures, what it is worth, and where we are still using a neutral default rather than guessing. Weighted across 7 components.
How this is measured6%
The market window around the issue date. This is currently a neutral placeholder: we have not yet wired it to index trend and recent listing performance, so it does not move the score in either direction.
How this is measured12%
Whether marquee anchor investors took part, and how many. Held at a neutral 50 when no marquee anchor is identified in the filing.
How this is measured10%
Whether fresh capital actually enters the business. A predominantly offer-for-sale issue is marked down ONLY when the financials are weak. A profitable, cash-rich company selling down is treated as neutral, not penalised, because it does not need the money.
How this is measured24%
Taken from the three-year numbers in the filing: whether the company was profitable in the latest year, and whether profit is rising or falling across the disclosed period.
How this is measured16%
Where the multiples printed in the filing sit against the peer median. When the filing does not disclose comparable peer multiples, this is held at a neutral 55 rather than guessed.
How this is measured14%
A proxy for syndicate strength, based today only on how many lead managers are on the issue. It sits at a neutral 60 unless three or more banks are involved. We have not yet built a bank-by-bank track record, so treat this as a rough signal.
How this is measured18%
Starts at 100 and loses points for every material red flag we find in the filing: contingent liabilities, related-party intensity, customer concentration, litigation, auditor qualifications. This is the component our DRHP forensics drives directly.
3-Year Financial & Growth Trend
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| Revenue (₹ Cr) | 10335.751 | 8242.25 | 6171.632 |
| Net Profit (₹ Cr) | 916.519 | 1081.672 | 533.203 |
| PAT Margin | 8.87% | 13.12% | 8.64% |
Revenue Breakdown
- Hospital services: 94.71%
- Pharmacy sales: 4.15%
- Diagnostic services: 2.33%
- Other operating revenue: 0.74%
Market Context
NOT part of the FinMinutes ScoreThe Score above is what the filing says. Everything in this box is what the crowd says. We keep them apart on purpose — every other site blends the two and calls the result a rating. Demand is real information, but it is information about the market, not about the company, and it changes by the hour while the company does not.
Subscription is low early in a book and high at the end, because most bids arrive in the final hours. A number read on day one says more about the clock than the company — which is precisely why it is not in the Score. GMP is unofficial, unregulated, and easily moved. Neither is a recommendation.
Deep Financials
Revenue, EBITDA and profit are what every listing site prints. Below are the full restated statements as disclosed, the ratios we compute from them, and a DuPont decomposition of the return on equity. A prospectus carries three years, not ten — that is the document’s ceiling, and within it we go as deep as it allows.
Income StatementThe full profit and loss as restated in the filing.
| Income Statement (₹ Cr) | FY26 | FY25 | FY24 |
|---|---|---|---|
| Revenue from Operations | 10,335.75 | 8,242.25 | 6,171.63 |
| Other Income | 184.77 | 120.54 | 93.54 |
| Total Income | 10,520.52 | 8,362.79 | 6,265.17 |
| Cost of Materials Consumed | 2,116.16 | 1,680.04 | 1,251.21 |
| Employee Benefit Expense | 1,490.04 | 1,219.41 | 857.04 |
| Other Expenses | 4,118.39 | 3,216.27 | 2,380.32 |
| Total Expenses | 9,268.42 | 7,134.43 | 5,340.51 |
| Depreciation & Amortisation | 679.55 | 506.84 | 397.02 |
| Finance Cost | 864.29 | 511.87 | 454.93 |
| Profit Before Tax | 1,178.03 | 1,242.31 | 745.04 |
| Tax Expense | 261.51 | 160.64 | 211.83 |
| Profit After Tax | 916.52 | 1,081.67 | 533.20 |
| EPS - Basic | 7.71 | 9.25 | 5.27 |
| EPS - Diluted | 7.67 | 9.25 | 5.25 |
Balance SheetWhat the company owns, owes, and is worth on paper.
| Balance Sheet (₹ Cr) | FY26 | FY25 | FY24 |
|---|---|---|---|
| Share Capital | 235.95 | 77.06 | 75.63 |
| Reserves & Surplus | 8,190.14 | 5,770.28 | 3,939.91 |
| Net Worth | 8,426.09 | 5,847.34 | 4,015.54 |
| Long-term Borrowings | 9,948.81 | 4,469.98 | 3,700.14 |
| Short-term Borrowings | 604.62 | 296.85 | 243.85 |
| Total Borrowings | 10,553.43 | 4,766.83 | 3,943.98 |
| Trade Payables | 1,464.54 | 1,126.59 | 1,130.52 |
| Current Liabilities | 3,362.37 | 1,794.80 | 1,656.74 |
| Total Liabilities | 16,065.74 | 8,071.90 | 6,731.32 |
| Property, Plant & Equipment | 5,840.79 | 4,224.73 | 3,750.24 |
| Capital Work in Progress | 795.30 | 614.03 | 41.59 |
| Intangible Assets | 2,406.39 | 502.67 | 424.49 |
| Investments | 2,675.19 | 1,775.67 | 1,121.09 |
| Inventories | 169.85 | 131.93 | 103.18 |
| Trade Receivables | 929.76 | 637.30 | 458.88 |
| Cash & Equivalents | 299.35 | 291.28 | 360.88 |
| Current Assets | 4,102.50 | 2,848.12 | 2,051.45 |
| Total Assets | 24,864.50 | 14,072.08 | 10,818.83 |
Cash FlowWhere the cash actually went. Often the most honest statement of the three.
| Cash Flow (₹ Cr) | FY26 | FY25 | FY24 |
|---|---|---|---|
| Net Cash from Operating Activities | 2,078.40 | 1,569.83 | 1,388.65 |
| Capital Expenditure | 1,316.19 | 1,054.31 | 331.94 |
| Net Cash from Investing Activities | -7,036.74 | -2,658.34 | -870.50 |
| Net Cash from Financing Activities | 4,954.44 | 904.08 | -250.21 |
| Net Change in Cash | -3.90 | -184.43 | 267.94 |
Ratio AnalysisProfitability, leverage, liquidity, efficiency and earnings quality — computed by us.
Every ratio below is computed by us from the line items the company disclosed — not copied from anywhere. The arithmetic is standard; the point is that somebody actually did it. Blank cells mean the filing did not disclose the inputs, and we would rather show a gap than invent a number.
| Ratio | FY26 | FY25 | FY24 |
|---|---|---|---|
| Profitability | |||
| EBITDA Margin (%) | 25.9 | 27 | 25.5 |
| EBIT Margin (%) | 19.4 | 21 | 19.2 |
| PAT Margin (%) | 8.9 | 13.1 | 8.6 |
| Return on Equity (%) | 10.9 | 18.5 | 13.3 |
| Return on Capital Employed (%) | 10.8 | 16.5 | 15.1 |
| Return on Assets (%) | 3.7 | 7.7 | 4.9 |
| Leverage | |||
| Debt / Equity (x) | 1.25 | 0.82 | 0.98 |
| Net Debt / EBITDA (x) | 3.77 | 1.98 | 2.24 |
| Interest Coverage (x) | 2.36 | 3.43 | 2.64 |
| Liquidity | |||
| Current Ratio (x) | 1.22 | 1.59 | 1.24 |
| Quick Ratio (x) | 1.17 | 1.51 | 1.18 |
| Efficiency | |||
| Asset Turnover (x) | 0.42 | 0.59 | 0.57 |
| Receivable Days | 33 | 28 | 27 |
| Inventory Days | 6 | 6 | 6 |
| Payable Days | 52 | 50 | 67 |
| Cash Conversion Cycle (days) | -13 | -16 | -34 |
| Quality of Earnings | |||
| Operating Cash Flow / PAT (x) | 2.27 | 1.45 | 2.6 |
| Accruals Ratio (%) | -4.7 | -3.5 | -7.9 |
| Capex / Depreciation (x) | 1.94 | 2.08 | 0.84 |
DuPont DecompositionWhy the return on equity is what it is: margin, efficiency, or leverage.
A headline return on equity tells you what. The DuPont decomposition tells you why — whether the return is earned through margin, through asset efficiency, or simply through leverage. Two companies can post an identical ROE for opposite reasons, and only one of them is safe.
| Component | FY26 | FY25 | FY24 |
|---|---|---|---|
| Net Margin (PAT / Revenue) | 8.9% | 13.1% | 8.6% |
| Asset Turnover (Revenue / Assets) | 0.42x | 0.59x | 0.57x |
| Equity Multiplier (Assets / Net Worth) | 2.95x | 2.41x | 2.69x |
| = Return on Equity | 10.9% | 18.5% | 13.3% |
| Tax Burden (PAT / PBT) | 0.78x | 0.87x | 0.72x |
| Interest Burden (PBT / EBIT) | 0.58x | 0.71x | 0.62x |
| Operating Margin (EBIT / Revenue) | 19.8% | 21.3% | 19.4% |
Computed from the disclosed statements. Where the filing omits an input, the row is left blank rather than estimated.
Quality of EarningsWhat the statements say when you read them against each other.
What the statements say once you read them against each other. These are observations, not verdicts — every one is arithmetic on the numbers the company itself disclosed, and each is stated so you can go and check it in the filing.
- Operating cash flow was 2.27x reported profit in FY26. Earnings are converting into cash, which is what you want to see and frequently is not the case.
Forensic ModelsBeneish, Altman and Piotroski — plus our own final-year check.
Beneish M-Score
M = -2.3An eight-variable model built to detect earnings manipulation, and built to run on exactly two consecutive years — which is what a prospectus gives us. It belongs here more than anywhere: a company about to list has the maximum possible incentive to have dressed up the very years it is about to show you. A score above −1.78 is the threshold at which the model says the accounts merit a closer look. It is a screening signal, not an accusation, and it was calibrated on listed companies elsewhere. Read the eight components, not just the total.
| Component | Value | What it captures |
|---|---|---|
| DSRI Days Sales in Receivables Index (Receivables_t / Sales_t) / (Receivables_t-1 / Sales_t-1) | 1.163 | Above 1 means receivables grew faster than sales. Revenue may be being recognised ahead of collection. |
| GMI Gross Margin Index GrossMargin_t-1 / GrossMargin_t | 1.001 | Above 1 means margins deteriorated. A firm with worsening prospects has more incentive to manipulate. |
| AQI Asset Quality Index AQ_t / AQ_t-1, where AQ = 1 - (CurrentAssets + PPE) / TotalAssets | 1.207 | Above 1 means a rising share of assets is soft (neither current nor fixed) — capitalised costs can hide here. |
| SGI Sales Growth Index Sales_t / Sales_t-1 | 1.254 | Growth is not manipulation. But high-growth firms face more pressure to keep the streak going. |
| DEPI Depreciation Index DepRate_t-1 / DepRate_t, where DepRate = Dep / (Dep + PPE) | 1.028 | Above 1 means assets are being depreciated more slowly — a quiet way to lift reported profit. |
| SGAI SG&A Index (SGA_t / Sales_t) / (SGA_t-1 / Sales_t-1), SGA proxied as employee cost + other expenses | 1.008 | A proxy, because filings rarely break out SG&A cleanly. Read it as a direction, not a precise figure. |
| LVGI Leverage Index Leverage_t / Leverage_t-1, where Leverage = (CurrentLiab + LongTermDebt) / TotalAssets | 1.203 | Above 1 means leverage rose. Debt covenants create pressure to hit numbers. |
| TATA Total Accruals to Total Assets (PAT - CashFromOperations) / TotalAssets | -0.0467 | The gap between reported profit and cash generated. The single heaviest term in the model — and the one that catches profit that never became cash. |
M = -2.3, below the −1.78 threshold. The model does not flag these accounts.
Altman Z″-Score (emerging markets)
Z″ = 5.62 · SafeA distress-prediction model. We use the Z″ variant deliberately: the original Z was calibrated on American manufacturers and misleads badly on Indian services companies. Above 2.6 is the safe zone, 1.1 to 2.6 is grey, below 1.1 is the distress zone. Like every model of its kind it is a screen, not a prophecy.
| X1 — Working Capital / Total Assets | 0.03 |
| X2 — Retained Earnings / Total Assets | 0.329 |
| X3 — EBIT / Total Assets | 0.082 |
| X4 — Net Worth / Total Liabilities | 0.524 |
| Z″ = 3.25 + 6.56·X1 + 3.26·X2 + 6.72·X3 + 1.05·X4 | 5.62 |
Piotroski F-Score (adapted)
3 / 8Nine yes-or-no tests of fundamental strength — except we run eight. One of the original nine asks whether the company issued new shares, which is plainly absurd to ask of a company whose entire purpose at this moment is to issue shares. We drop that test and score out of eight, and we would rather tell you that than quietly fudge it.
- ✓Positive return on assets
- ✓Positive operating cash flow
- ✗Return on assets improving
- ✓Cash flow exceeds profit (quality of earnings)
- ✗Long-term leverage decreasing
- ✗Current ratio improving
- ✗Gross margin improving
- ✗Asset turnover improving
The Final-Year Check
oursNot from any textbook. The hockey stick in the last year before a filing is the oldest pattern in this business, and nobody publishes it. So we measure it: how the final disclosed year compares with the years behind it. Real acceleration looks exactly the same on the page as a flattering one — which is precisely why it is worth naming rather than assuming either way.
- Profit moved backwards in FY26: net profit fell 15.3% to ₹917 cr even as revenue grew 25.4% to ₹10,336 cr. Net margin compressed from 13.1% to 8.9%. A premium multiple asked on a year when earnings moved backwards is worth understanding: the profit the price is measured against is not the peak the company has shown.
Ratios Nobody Prints
- Contingent liabilities / Net worth: 1.7%
Contingent liabilities of 146.31 cr against a net worth of 8,426.09 cr — 1.7% of what the company is worth on paper. These are obligations that sit off the balance sheet but could land on it. What they consist of matters as much as the size: a corporate guarantee to a subsidiary is a different animal from a disputed tax demand, and the filing says which. - Related-party revenue / Total revenue: 0.6%
0.6% of revenue in FY26 came from entities connected to the promoters. Revenue you sell to yourself is not the same as revenue you won in the market. - Cash / Short-term borrowings: 0.5x
Short-term borrowings of 604.62 cr against cash of 299.35 cr. Debt that must be refinanced within a year is only comfortable while lenders stay comfortable. - Promoter remuneration / PAT: 3.5%
Managerial remuneration to the promoter group was 32.46 cr against a profit of 916.52 cr. This is a legitimate cost — but it is also a route by which value leaves a company before it ever reaches a minority shareholder.
The Formula NotebookEvery number above, with the working shown. Check us.
Every number we publish, with the working shown. The formula, the same formula with this company’s actual figures put into it, the answer, and what it is for. Check us. That is the point.
PAT ÷ Net Worth916.52 ÷ 8,426.09What the company earned on the money shareholders have in it. The headline measure of return — and the one the DuPont section takes apart.
EBIT ÷ (Net Worth + Total Borrowings)2,042.32 ÷ (8,426.09 + 10,553.43) = 2,042.32 ÷ 18,979.53Return on ALL the capital in the business, borrowed as well as owned. Unlike ROE, it cannot be flattered by taking on debt.
EBITDA ÷ Revenue2,721.87 ÷ 10,335.75Operating profitability before the effects of debt, tax and depreciation. What the business earns from the act of trading.
Total Borrowings ÷ Net Worth10,553.43 ÷ 8,426.09How much the company has borrowed against what it owns. High is not automatically bad — ask whether the borrowing is being serviced comfortably.
EBIT ÷ Finance Cost2,042.32 ÷ 864.29How many times over operating profit covers the interest bill. Below about 2x, a meaningful share of what the business earns is going to lenders rather than owners.
(Trade Receivables ÷ Revenue) × 365(929.76 ÷ 10,335.75) × 365How long the company waits to be paid. Rising receivable days mean revenue is being booked faster than it is collected — which is where a great many accounting problems begin.
Inventory Days + Receivable Days − Payable Days6 + 33 − 52How long cash is tied up in the operating cycle before it comes back. The longer it is, the more working capital the business must fund.
Cash from Operations ÷ PAT2,078.40 ÷ 916.52Did the profit turn into cash? Profit is an opinion; cash is a fact. When this sits well below 1x for long, the two are drifting apart, and the filing is where you find out why.
(PAT − Cash from Operations) ÷ Total Assets(916.52 − 2,078.40) ÷ 24,864.50 = -1,161.88 ÷ 24,864.50The share of reported profit that exists on paper rather than in the bank. It is also the heaviest single term in the Beneish model, for good reason.
Price × Post-issue Shares₹590.00 × 1,315,350,541 sharesWhat the whole company is being valued at, if the issue prices at the top of the band.
Market Cap + Total Borrowings − Cash77,605.68 + 10,553.43 − 299.35What it would actually cost to buy the whole business: you take on its debt and you get its cash. This is the number a buyer cares about, and it is the reason a P/E on its own can mislead.
Enterprise Value ÷ EBITDA87,859.76 ÷ 2,721.87The multiple that includes debt. Two companies on the same P/E — one debt-free, one heavily borrowed — are not the same investment, and only this number tells you so.
Market Cap ÷ PAT77,605.68 ÷ 916.52The familiar multiple. Useful, but blind to debt — read it alongside EV/EBITDA, never instead of it.
EBIT × (1 − tax rate) ÷ (Net Worth + Debt − Cash)NOPAT ÷ Invested CapitalWhat the business earns on the capital actually at work in it. We do not compare this to a cost of capital: that would need a beta, an unlisted company has none, and inventing one would be theatre.
Workspace
The numbers are already loaded. Move the offer price and watch every multiple move with it. Set your own growth and margin and see what they imply two years out. These are your assumptions, not our forecast — we have no view on what this company will earn, and the moment we published one we would be doing something we are not registered to do. What we can do is put the arithmetic in front of you and get out of the way.
Price defaults to the top of the band. Margin defaults to what the company actually reported in FY26.
Projections are arithmetic on the inputs you typed. They are not a forecast, not a recommendation, and not a view on whether this offer is worth taking. Educational only.
Institutional Alpha: DRHP Deep Dive
The Indian healthcare delivery market is experiencing robust expansion, driven by rising life expectancy, increasing incidence of non-communicable and lifestyle diseases, expanding health insurance coverage, and rising medical tourism. The market is predominantly skewed toward private healthcare providers, who are expanding infrastructure to meet the demand for high-quality, specialized treatments. Cardiac sciences and oncology represent the largest specialty segments. For leading pan-India chains like Manipal, growth is propelled by the growing need for complex tertiary and quaternary care, digital healthcare integration, and ongoing industry consolidation, where large networks acquire regional players to deepen micro-market penetration and leverage economies of scale.
Future Planning & Capital Allocation
The company is executing a massive ₹80,000 million Fresh Issue primarily designed to deleverage the balance sheet. Specifically, ₹55,527.60 million will be used to prepay/repay outstanding borrowings of its material subsidiary, MHPL, and ₹5,740.00 million will fund the acquisition of the remaining minority stake in the recently acquired Sahyadri Hospitals. This aggressive debt reduction will significantly cut the group's finance costs (which stood at ₹8,642.89 million in FY26) and further expand net profit margins.
Source: RHP p. 32, 146, 192, 399Competitive Position
Manipal has cemented its position as the apex consolidator in the Indian private hospital space, completing major acquisitions including Columbia Asia, AMRI, Medica Synergie, and Sahyadri. By focusing its clinical mix heavily on complex tertiary and quaternary care (CONGO-R specialties), it commands pricing power and longer-term patient stickiness, differentiating itself from regional secondary-care providers.
Source: RHP p. 228, 261, 298Execution / Track Record
The company's execution of its M&A strategy is demonstrably successful. Consolidated revenue expanded from ₹61,716 million in FY24 to ₹103,357 million in FY26 while maintaining a robust Adjusted EBITDA margin of 25.58%. Management has proven its ability to extract synergies and implement stringent working capital discipline, operating with a negative 13-day working capital cycle in FY26 despite incorporating multiple distinct hospital chains into its network.
Source: RHP p. 300, 301, 588Shareholding, Syndicate & Leadership
Leadership & Skin in the Game
Leadership: Dilip Jose (Managing Director and Chief Executive Officer)
Litigation: Against Company: 1 criminal, 40 tax, and 4 statutory/regulatory proceedings aggregating to ₹2,963.36 million. Against Subsidiaries: 9 criminal, 180 tax, 30 statutory/regulatory, and 3 civil proceedings aggregating to ₹5,041.54 million.
Auditor / RPT Flags: CARO/Other Matter qualifications: The audit trail (edit log) facility was not enabled at the database level to log direct data changes in the accounting software used by the Company and several Subsidiaries. Further, CARO observations noted undisputed delays in statutory dues (bonus and provident fund) and significant loans (₹4,539 million) granted to a subsidiary that were settled via extension of further loans.
Peers & Valuation
| Company | P/E | P/B | RoE | Margin |
|---|---|---|---|---|
| Apollo Hospitals Enterprise Ltd | 73.23 | — | 17.61 | — |
| Fortis Healthcare Ltd | 80.12 | — | 8.68 | — |
| Max Healthcare Institute Ltd | 87.63 | — | 11.47 | — |
| Aster DM Healthcare Limited | 85.94 | — | 4.39 | — |
| Global Health Limited | 63.85 | — | 15.68 | — |
| Krishna Institute of Medical Sciences Limited | 54.34 | — | 15.55 | — |
| Narayana Hrudayalaya Limited | 57.06 | — | 27.88 | — |
Hospital Vitals
The operating metrics that actually price this business — the ones a generic IPO page skips. Straight from the filing.
| Metric | Value | Detail |
|---|---|---|
| Operational beds | 6,227 | Actuals as of FY26 across 49 hospitals (6,878 operational beds on a pro forma basis) |
| Occupancy rate | 64.47% | Actuals for FY26; down from 67.09% in FY25 |
| ARPOB | ₹68,937.61 | Average revenue per occupied bed per day in FY26 (actuals); up from ₹63,312.23 in FY25 |
| ALOS | 2.78 days | Average length of stay in FY26 (actuals); decreased from 2.88 days in FY25 |
| Bed additions planned | 2,426 beds | Planned capacity expansion through FY30 and beyond |
| Payor mix | Cash 30.33%, Insurance/TPA 49.68%, Govt 13.80%, Others 6.19% | Gross inpatient revenue split for FY26 (actuals) |
| Doctor count | 11,064 doctors | As of March 31, 2026 across the network |
| Patient volume | 527,227 IP / 5,483,403 OP | Inpatient vs Outpatient footfalls for FY26 (actuals) |
Source: RHP p. 550-554 — Management's Discussion and Analysis / Business
🔍 Forensic Findings — What the Footnotes Say
Risks hiding outside the risk section — mined from MD&A, related-party notes, contingent liabilities and litigation. This is the FinMinutes edge.
The statutory auditors issued adverse remarks under Other Legal and Regulatory Requirements stating that the company and its subsidiaries used accounting software where the audit trail (edit log) facility was not enabled at the database level to log direct data changes, and at the application level it was only implemented in a phased manner or not enabled throughout the year.
RHP p. 134-138The company recognized significant impairment charges on recent investments, including a ₹1,140.65 million goodwill impairment for HealthMap Diagnostics Private Limited in FY24 and a ₹222.32 million full impairment of its investment in associate Medica TS Hospital Private Limited in FY25.
RHP p. 83, 95Certain historical corporate records are untraceable, potentially exposing the company to regulatory proceedings, actions, or penalties by competent regulatory authorities.
RHP p. 87, 639CARO 2024 observations noted that loans aggregating to ₹4,539.00 million granted by the Company to Manipal Hospitals (Dwarka) Private Limited fell due during FY24 and were settled by the extension of fresh loans to the same party.
RHP p. 138, 475Against Company: 1 criminal, 40 tax, and 4 statutory/regulatory proceedings aggregating to ₹2,963.36 million. Against Subsidiaries: 9 criminal, 180 tax, 30 statutory/regulatory, and 3 civil proceedings aggregating to ₹5,041.54 million.
RHP p. 104, 134-138, 146, 386, 448, 613CARO/Other Matter qualifications: The audit trail (edit log) facility was not enabled at the database level to log direct data changes in the accounting software used by the Company and several Subsidiaries. Further, CARO observations noted undisputed delays in statutory dues (bonus and provident fund) and significant loans (₹4,539 million) granted to a subsidiary that were settled via extension of further loans.
RHP p. 104, 134-138, 146, 386, 448, 613Company's Claims vs Reality
We stress-test each claim against the filing's own data.
Does the independent industry report validate this market leadership position?
RHP p. 200, 228 (Confirmed by CRISIL Report; 13,037 licensed beds across 49 hospitals)Do the financials reflect successful integration and margin expansion?
RHP p. 201, 588 (Revenue grew at 29.41% CAGR and Adjusted EBITDA Margin remained robust at 25.58% in FY26 despite integrating multiple large acquisitions like AMRI and Sahyadri)Proprietary SWOT — Company-Specific
Strengths
- Market leader as India's largest multispecialty hospital network by bed capacity (13,037 beds) with a highly successful, repeatable playbook for integrating major acquisitions.
- Industry-leading growth with strong profitability; Revenue from operations grew at 29.41% CAGR (FY24-FY26), backed by highly efficient working capital management resulting in a negative working capital cycle of 13 days in FY26.
Weaknesses
- High geographic concentration risk, with 46.40% of restated consolidated revenue in FY26 derived from hospitals located in a single state, Karnataka.
Opportunities
- Significant growth potential in high-acuity 'CONGO-R' specialties (cardiac, oncology, neurosciences, gastro, orthopedics, renal) which already account for over 64% of gross inpatient revenue and drive higher Average Revenue Per Occupied Bed (ARPOB).
- Consolidation of the fragmented Indian private healthcare delivery market, allowing the company to further deploy its M&A playbook in underserved Tier-2 and Tier-3 micro-markets.
Threats (material, not boilerplate)
- High dependence on insurance and Third-Party Administrators (TPAs). risk_section
Why it matters: 49.68% of gross inpatient revenue in FY26 was derived from insurance and TPAs. Delays, non-renewals, or disputes over billing with these entities could severely impact the company's negative working capital cycle and liquidity. - Contingent liabilities and ongoing tax litigation. footnotes
Why it matters: The group faces ₹1,463.09 million in contingent liabilities, including substantial direct and indirect tax demands (₹1,041.43 million). Adverse rulings could strain cash flows.
Analyst Q&A: Burning Questions
Facts from the filing. No recommendation — that layer arrives once our Research Analyst registration is live.
Where is the money going?
The Offer includes a Fresh Issue of ₹80,000 million. The proceeds are heavily weighted toward deleveraging: ₹55,527.60 million will be used to repay/prepay outstanding borrowings of subsidiary Manipal Hospitals Private Limited, and ₹5,740.00 million will be used to acquire a minority stake in step-down subsidiary Sahyadri Hospitals Private Limited.
RHP p. 146How concentrated is the geographic and payor base?
Geographically, the company relies heavily on Karnataka, which generated 46.40% of its operating revenue in FY26. From a payor perspective, 49.68% of gross inpatient revenue in FY26 came from Insurance/TPAs, followed by Cash/Self-pay at 30.33%, and Government Schemes at 13.78%.
RHP p. 79, 305Is it profitable and growing?
Yes. Revenue from operations grew rapidly from ₹61,716.32 million in FY24 to ₹103,357.51 million in FY26. Concurrently, Profit After Tax increased from ₹5,332.03 million to ₹9,165.19 million, yielding an Adjusted EBITDA margin of 25.58% and a Return on Capital Employed (ROCE) of 21.88% in FY26.
RHP p. 399, 588What sits in the footnotes / contingent liabilities?
The company reported ₹1,463.09 million in contingent liabilities as of FY26, primarily consisting of disputed direct/indirect tax demands (₹1,041.43 million) and patient compensation claims (₹180.54 million). Footnotes also disclose auditor CARO qualifications regarding the company's accounting software lacking required database-level audit trails, and ₹1,362.97 million in historical impairment write-offs related to goodwill and associate investments.
RHP p. 83, 134-138, 437What Earlier Investors Paid
Early capital takes real risk and is fairly rewarded for it — a large multiple built over many years is normal. What deserves a closer look is a steep step-up in a short window: a round priced cheaply only months before the offer.
| Shareholder | Priced at | When | vs IPO price |
|---|---|---|---|
| Manipal Research & Management Services International | ₹58.45 | 2026-07-14 | 10.1x |
| This round priced within the last year, yet the offer is at roughly 10.1x that price. A step-up this steep in this little time is worth understanding: what changed in the business to justify it? | |||
| The 1 allotments below are shown at their as-disclosed per-share price. These prices are not adjusted for any later bonus issue or share split, so where the company has issued bonus shares the raw multiple understates the true return and can even read as a loss when none was made. We show them as filed and decline to compute a misleading multiple. Bonus-adjusted cost is on the roadmap. | |||
| MEMG International India Private Limited | ₹692.68 | 2026-03-12 | as disclosed |
Prices are as stated in the filing’s allotment history and are not adjusted for later bonus issues or share splits. Where a company has issued bonus shares, the multiples above understate the true return and can even read as losses. Adjusting for that is on our list; until it is done we would rather show the raw disclosure and tell you its limits than publish a confident number that is wrong.
Lock-in Expiry Calendar
Shares held before the IPO cannot be sold immediately; they unlock in tranches. When a tranche unlocks, more shares become eligible to trade. Retail investors are frequently caught unaware by these dates. The schedule below follows from the listing date; quantities are shown only where the filing discloses them.
- 05 Aug 2029Minimum Promoters' Contributionthree years
- 05 Aug 2027Promoters' shareholding in excess of 20%one year
- 05 Feb 2027Balance pre-Offer Equity Share capitalsix months
- 03 Nov 2026Anchor Investors (50%)90 days
- 04 Sep 2026Anchor Investors (50%)30 days
An unlock means more shares may be sold — not that they will be, and not that the price will move. We state the dates; what you do with them is your call.
What Changed Between the DRHP and the RHP
Companies file a draft prospectus, then a final one. The changes in between are rarely reported, and they can be revealing.
| Item | In the DRHP | In the RHP / Addendum |
|---|---|---|
| Offer for Sale (OFS) Size The Investor Selling Shareholders (Ammar Sdn Bhd, Novo Holdings, and Phoenix Bear) reduced the number of shares offered in the OFS by exactly 50% between the draft and final filings. | Included up to 811,582 shares by Ammar Sdn Bhd, 529,111 shares by Novo Holdings Invest Asia A/S, and 440,926 shares by Phoenix Bear Investments, LLC. | OFS of up to 21,613,834 Equity Shares. The specific offerings were reduced to 405,791 shares by Ammar Sdn Bhd, 264,556 shares by Novo Holdings, and 220,463 shares by Phoenix Bear. |
| Financial Information Period The restated financial statements were rolled forward to include the full FY26, dropping the six-month interim period and FY23. | Restated financial statements for the six months ended September 30, 2025, and the financial years ended March 31, 2025, 2024, and 2023. | Restated financial statements for the financial years ended March 31, 2026, 2025, and 2024. |
| Pre-IPO Share Transfers (Promoter Group) The upside sharing agreement transfer was executed between the DRHP and RHP filings, resulting in a 5.12 million share secondary transfer from an investor to the promoter group. | TPG SG Magazine Pte. Ltd. agreed to transfer up to 6,000,000 Equity Shares to Manipal Research & Management Services International (MRMSI) prior to filing the RHP. | On July 14, 2026, exactly 5,123,543 Equity Shares were transferred from TPG SG Magazine Pte. Ltd. to MRMSI at ₹58.45 per share. |
| Contingent Liabilities Total contingent liabilities decreased by roughly 20%, primarily due to a reduction in indirect tax demands. | ₹1,838.59 million (as of September 30, 2025) | ₹1,463.09 million (as of March 31, 2026) |
| Regulatory Litigation / RBI Compounding The RHP includes material updates on pending RBI FEMA/compounding issues that arose or advanced after the DRHP was filed. | MHSPL filed a compounding application on March 4, 2026, with the RBI regarding downstream investments. | The RBI directed the Company on June 18, 2026, to re-submit the compounding application. MHSPL was also advised in late April 2026 to file an additional compounding application for FC-TRS filings. |
Educational, grounded entirely in the company's filings (DRHP/RHP). Not investment advice. FinMinutes does not provide buy/sell recommendations.